

## **Prematurely ended - Statement**

<b>EudraCT Number:</b>	2008-005786-60
<b>Full title of the study:</b>	A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours.
<b>Sponsor-Code:</b>	FET PET 2010
<b>Sponsor:</b>	Charité – Universitätsmedizin Berlin
<b>Principal Investigator/ Study Contact::</b>	PD Dr. med. Pablo Hernáiz Driever Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Pädiatrie m.S. Onkologie/Hämatologie, Augustenburger Platz 1, D - 13353 Berlin  <a href="mailto:pablo.hernai@charite.de">pablo.hernai@charite.de</a>
<b>Product:</b>	IMP O-(2-[18F] Fluoro-Ethyl-L-Tyrosine, up to 200MBq/ml , injection solution (Euro PET, Germany)
<b>Date of early termination:</b>	2018/11/20
<b>Statement:</b>	Due to difficulties in recruitment, study enrolment was terminated before the targeted sample size was achieved. Within the last 5 1/2 years (vote 24.05.2013) only 10% of patients could be recruited. No patient received treatment at time of early termination. The primary and secondary endpoints cannot be reached due to the small number of patients. There are no consequences for overall risk benefit assessment of the IMP.